An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China

Trial Profile

An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Xian-Janssen
  • Most Recent Events

    • 06 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 14 Apr 2017 Planned initiation date changed from 22 Mar 2017 to 14 Apr 2017.
    • 12 Mar 2017 Planned initiation date changed from 1 Mar 2017 to 22 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top